Doctor's Orders

Herper, Matthew
December 2005
Forbes Asia;12/26/2005, Vol. 1 Issue 9, p81
The article speculates on strategies that Merck could use to recover from losses. The company's CEO Richard Clark, calls eliminating 7,000 positions, or 11% of the payroll, the first step toward righting the ailing company. Further steps could be cut the 13,000-representative sales force, ending a decade-long drug industry arms race. It could buy Schering Plough. Or it could give back a dividend yield.


Related Articles

  • Merck selects Richard Clark as new CEO.  // Chemical Market Reporter;5/9/2005, Vol. 267 Issue 19, p4 

    Reports on the appointment of Richard Clark as president and chief executive officer of Merck & Co. following the resignation of Raymond Gilmartin. Job responsibilities of Clark; Career background.

  • Big Bucks for Merck's Clark Amid Vioxx Pain. P., Shankar // njbiz;3/17/2008, Vol. 21 Issue 12, p2 

    The article reports on the increase in base salary of Richard T. Clark, president and chief executive officer of Merck & Co. According to a regulatory filing, Clark gets an 11 percent increase in his base salary to $1.8 million effective in March 2008. Information is presented on the total...

  • Merck appoints CEO.  // BRW;5/12/2005, Vol. 27 Issue 18, p81 

    Reports that pharmaceutical maker Merck promoted Richard Clark to chief executive officer following the departure of Raymond Gilmartin. Decline in profits after stopping sales of painkiller Vioxx; Advice of the United States Food and Drug Administration and European Medicines Agency; Heart...

  • Merck swoops in on Schering-Plough.  // Pharmaceutical Technology Europe;Apr2009, Vol. 21 Issue 4, p8 

    The article reports on the merger agreement between Merck and Co. Inc. and Schering-Plough Corp. to create a new pharmaceutical giant. Furthermore, it notes that the move will expand Merck's portfolio of medicines and will double the number of potential medicines that the company has in the...

  • Standing Behind Our Core Values. Clark, Richard T. // Vital Speeches of the Day;1/15/2006, Vol. 72 Issue 7, p220 

    The article presents a speech by Merck & Co. Inc. president and CEO Richard T. Clark, delivered at the Merck Strategy Meeting Whitehouse Station, New Jersey, December 15, 2005. He talks about the litigation and related controversies faced by the research-based pharmaceutical company. He...

  • A NEW CEO'S RX FOR WHAT AILS MERCK. Simons, John // Fortune;5/30/2005, Vol. 151 Issue 11, p28 

    Discusses the outlook for Merck's new chief executive officer (CEO), Richard T. Clark, who replaces outgoing CEO Raymond Gilmartin. Background on Clark; Management style; Comments of Clark; Signs of change at the company; Why Clark was chosen for the job; Mention of the recall of Merck's drug...

  • Merck chief quits as further material on Vioxx emerges. Moynihan, Ray // BMJ: British Medical Journal (International Edition);5/14/2005, Vol. 330 Issue 7500, p1101 

    Highlights the resignation of Raymond Gilmartin, chairman and CEO of the Merck & Co. Inc. Controversy surrounding the withdrawal of Merck's anti-arthritis drug, Vioxx, from the market due to evidence of dangerous side effects; Details of report by the U.S. Congress in which critiqued Merck's...

  • How to be a 'king maker' Gooch, Heather // Pest Control;Aug2004, Vol. 72 Issue 8, p19 

    Focuses on the strategy of chief executive officer C. B. Knox of Brown Exterminating Co. in business. Business model of Knox; Recruitment of experienced salespeople; Role of technology with the growth of the company. INSETS: The Brown mission statement;Of life and loyalty;Branding a better...

  • Factory guy LaSorda makes NADA debut. Wernle, Bradford // Automotive News;1/29/2007, Vol. 81 Issue 6240, p8 

    The article reports that Tom LaSorda, CEO of Daimlerchrysler AG, addressed a couple hundred Chrysler sales and marketing staffers during the Chrysler group's Detroit auto show. LaSorda said that regaining dealers' trust is critical to the success of the restructuring he is overseeing. LaSorda,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics